RESUMO
The authors prospectively examined elderly patients diagnosed with major depression with psychotic features (MD-P) and patients diagnosed with dementia of the Alzheimer Type (DAT) for neuroleptic-induced parkinsonism (NIP) during perphenazine treatment. Baseline parkinsonian symptoms did not differ between groups. With treatment, mean NIP score doubled in DAT patients but remained unchanged in the MD-P group. The difference between groups was highly significant and remained so after the effects of age, perphenazine dose, and duration of perphenazine treatment were controlled. Although the mechanisms underlying these differences in NIP development remain to be determined, clinical guidelines for neuroleptic dosages in elderly patients need to account for variability in neuroleptic tolerance between diagnostic groups.
RESUMO
This study examined effects of nortriptyline and sertraline on the balance and stability of depressed geriatric inpatients. Body sway was measured with a stable force-platform at three timepoints: before starting antidepressant medication, 5-7 days after medication was initiated, and 1 week later. A group of healthy, unmedicated older volunteers was evaluated under the same conditions as patients. In sertraline-treated patients (n = 10), significant differences (P < 0.05) between baseline and the first week of treatment were found in the force-platform measurements of sway length (L) and area of the center of pressure (Ao), with patients' eyes both open and closed. This change in postural stability occurred in the absence of orthostatic hypotension. By the second week of treatment, neither variable was found to be significantly different from baseline. In the nonmedicated volunteers (n = 20) and in the group of patients receiving nortriptyline (n = 11), no significant changes in postural stability were found.